Rothschild & CO Asset Management Us Inc. Myriad Genetics Inc Transaction History

Rothschild & CO Asset Management Us Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$9.78 - $29.53 $8.7 Million - $26.3 Million	-889,892 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$20.93 - $35.1 $1.17 Million - $1.97 Million	-56,026 Reduced 5.92%	889,892 $24.2 Million
Q3 2019 Nov 08, 2019	SELL	$22.08 - $47.08 $152,352 - $324,852	-6,900 Reduced 0.72%	945,918 $27.1 Million
Q2 2019 Jul 25, 2019	BUY	$22.67 - $35.0 $2.88 Million - $4.45 Million	127,158 Added 15.4%	952,818 $26.5 Million
Q1 2019 May 08, 2019	BUY	$26.93 - $34.7 $22.2 Million - $28.7 Million	825,660 New	825,660 $27.4 Million

254

90.9M

100K

34K

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $1.23B
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

Get notified when there are updates to the investment portfolio of Rothschild & CO Asset Management Us Inc., based on Form 13F filings with the SEC.

Stay updated on Rothschild & CO Asset Management Us Inc. with notifications on news.